Form 8-K - Current report:
SEC Accession No. 0001564590-22-010094
Filing Date
2022-03-14
Accepted
2022-03-14 16:26:00
Documents
14
Period of Report
2022-03-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20220314.htm   iXBRL 8-K 37266
2 EX-99.1 abio-ex991_6.htm EX-99.1 90819
3 GRAPHIC gt0xjek35k53000001.jpg GRAPHIC 202155
  Complete submission text file 0001564590-22-010094.txt   543977

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA abio-20220314.xsd EX-101.SCH 5713
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20220314_lab.xml EX-101.LAB 19431
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20220314_pre.xml EX-101.PRE 11597
8 EXTRACTED XBRL INSTANCE DOCUMENT abio-8k_20220314_htm.xml XML 3521
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 22736967
SIC: 2835 In Vitro & In Vivo Diagnostic Substances